Ayisha Sharma

London

Breaking News Reporters at Endpoints News

Reporter @endpointsnews

Featured in: Favicon

citeline.com (+1) Favicon

informa.com (+3) Favicon

hercampus.com Favicon

clinicaltrialsarena.com Favicon

endpts.com Favicon

newsbreak.com Favicon

invesbrain.com Favicon

fintechreporteruk.com Favicon

theguardian.com Favicon

moneymagpie.com + 6 more

Articles

Lyra’s stock soars on Phase 3 success for chronic rhinosinusitis treatment

6 days ago | endpoints.news | Ayisha Sharma

Lyra Therapeutics’ shares shot up about 500% at market open on Monday after the biotech said its nasal implant improved signs of an inflammatory sinus … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B

6 days ago | endpts.com | Ayisha Sharma

In the biggest biopharma deal since January, Sanofi is bolstering its rare immunology offering by acquiring Blueprint Medicines for $9.1 billion. The French drugmaker has … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Immatics reports more early-stage data for melanoma cell therapy with pivotal trial underway

1 week ago | endpts.com | Ayisha Sharma

Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sanofi, Regeneron report underwhelming data for IL-33 antibody itepekimab, shares drop

1 week ago | endpts.com | Ayisha Sharma

Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, leaving the partners to patch together a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Oric locks down cash for Phase 3 prostate cancer trial with early data in hand

1 week ago | endpts.com | Ayisha Sharma

May 29, 2025 07:14 AM EDT Oric locks down cash for Phase 3 prostate cancer trial with early data in hand Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
A new dawn for psychedelics? Compass could be the first to find out

1 week ago | endpts.com | Ayisha Sharma

The summer of 2024 was a dark time for psychedelics. The sector was reeling after Lykos Therapeutics failed to secure FDA approval … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Strand Therapeutics reports promising start for mRNA cancer therapy

1 week ago | endpts.com | Ayisha Sharma

A Boston biotech with self-replicating mRNA technology has shared early data from its lead candidate for cancers that are refractory to immune checkpoint inhibitors. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Boundless changes plans for cancer drug after toxicity issues

1 week ago | endpts.com | Ayisha Sharma

Boundless Bio has hit the reset button in the face of toxicity issues, nixing ongoing treatment arms in an early-stage cancer study in favor of … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Gilead notches another Phase 3 win for Trodelvy in triple-negative breast cancer

2 weeks ago | endpts.com | Ayisha Sharma

Gilead’s Trodelvy has passed another late-stage test in certain patients with metastatic triple-negative breast cancer (TNBC) — a win the company says could pave the way … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Samsung Biologics to separate manufacturing and biosimilar businesses

2 weeks ago | endpts.com | Ayisha Sharma

Samsung Biologics is splitting apart its contract manufacturing and biosimilar development activities in a bid to enhance their competitiveness. Samsung Bio will become a pure … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.